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Abstract
Background: Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) is a pro-apoptotic
member of the Bcl-2 family induced under hypoxia. Low or absent expression has recently been
described in human tumors, including gastrointestinal tumors, resulting in poor prognosis. Little is
known about BNIP3 expression in invasive breast cancer. The aim of the present study was to
investigate the expression of BNIP3 in invasive breast cancer at the mRNA and protein level in
correlation with the hypoxic response and clinicopathological features.
Methods: In 40 cases of invasive breast cancer, BNIP3 mRNA in situ hybridization was performed
on frozen sections with a digoxigenin labeled anti-BNIP3 probe. Paraffin embedded sections of the
same specimens were used to determine protein expression of BNIP3, Hypoxia Inducible Factor 1
alpha (HIF-1α) and its downstream targets Glucose Transporter 1 (Glut-1) and Carbonic
Anhydrase (CAIX) by immunohistochemistry.
Results: BNIP3 mRNA was expressed in 16/40 (40%) of the cases and correlated with BNIP3
protein expression (p = 0.0218). Neither BNIP3 protein nor mRNA expression correlated with
expression of HIF-1α expression or its downstream targets. Tumors which showed loss of
expression of BNIP3 had significantly more often lymph node metastases (82% vs 39%, p = 0.010)
and showed a higher mitotic activity index (p = 0.027). BNIP3 protein expression was often nuclear
in normal breast, but cytoplasmic in tumor cells.
Conclusion: BNIP3 expression is lost in a significant portion of invasive breast cancers, which is
correlated with poor prognostic features such as positive lymph node status and high proliferation,
but not with the hypoxic response.
Background
Bcl-2/adenovirus E1B 19 kDa-interacting protein3
(BNIP3) is a member of the Bcl-2 family. The common
feature among all Bcl-2 family members is the presence of
one or several Bcl-2 homology domains, of which four
different domains have been identified. The proteins are
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divided according to these homology domains into pro-
and anti-apototic proteins [1]. In the anti-apoptotic
group, all four homology domains are present. In BNIP3
and many of the other pro-apoptotic proteins, only the
BH3 domain is present and BNIP3 therefore belongs to
the BH3-only family. BNIP3 protein is localized on the
outside of the mitochondrial membrane. Upon stimula-
tion it integrates into the mitochondrial membrane, lead-
ing to permeabilization of the transition pore and a
decrease of the mitochondrial membrane potential. This
results in chromatin condensation and DNA-fragmenta-
tion and finally apoptosis [2,3]. BNIP3-induced cell death
is caspase-independent and does not induce cytochrome c
release [2]. BNIP3 has also implicated in the induction of
autophagy/mitophagy [4,5].
Hypoxia has been described as an important inducer of
BNIP3 expression. The transcription factor Hypoxia
Inducible Factor (HIF-1α) is the key regulator of the
hypoxic response. Under normoxic conditions HIF-1α is
hydroxylated, followed by binding to Von Hippel Lindau
(VHL) protein and proteosomal degradation. Under
hypoxic conditions this hydroxylation does not occur,
and in case of VHL mutations proteosomal degradation is
prohibited, leading to HIF-1α stabilization, heterodimer-
ization with its constitutively expressed partner HIF-1β
and translocation to the nucleus, where it transactivates
hypoxia responsive genes by binding to a Hypoxia-
Responsive-Element (HRE) in their promoters. Among
the target genes of HIF-1α are genes involved in glycolysis,
angiogenesis and apoptosis [6]. Previous studies indicated
that HIF-1α enhances the expression of BNIP3 [6-8] and
that levels of BNIP3 protein usually parallel mRNA levels
[8]. Hypoxia-induced autophagy via BNIP3 has been
claimed to be a survival mechanism promoting tumor
progression [9].
Decreased levels of BNIP3 mRNA and protein have been
found in pancreatic cancer [10-12], colorectal and gastric
cancer [13], and hematopoietic malignancies [14]. On the
other hand, increased levels of BNIP3 protein have been
described in non-small cell lung cancer, where high
expression of BNIP3 protein was linked with a poor prog-
nosis [15,16]. In prostate cancer, there was a significant
correlation between cytoplasmic BNIP3 expression and
Gleason score, age, and Glut1, and between nuclear
BNIP3 expression and HIF-1α [17].
Only a few studies on BNIP3 expression in breast cancer
have been published. One study showed high BNIP3
mRNA expression in breast tumors compared to normal
tissue, especially in peri-necrotic tumor region [18].
BNIP3 mRNA was also strongly expressed in ductal carci-
noma in situ (DCIS) and correlated with a high grade phe-
notype and presence of invasive disease [19]. Another
study using an experimental mouse model showed that
expression of BNIP3 protein was inversely correlated with
the ability of tumor cells to metastasize. Knockdown of
BNIP3 increased tumor size and induced metastases [20].
A more recent study [21] suggested that upregulation of
BNIP3 protein expression plays a role in breast tumor pro-
gression. This study showed an increased disease-free sur-
vival in patients with ER-positive BNIP3 nuclear-positive
invasive tumors, but no associations with cytoplasmic
BNIP3. Furthermore they found no association between
HIF-1α and BNIP3.
In the present study we have investigated the expression of
BNIP3 in invasive breast cancer at the mRNA and protein
level in correlation with the hypoxic response and clinico-
pathological features. For the hypoxic response, we exam-
ined HIF-1α as the key regulator and two of its target
genes, Glucose Transporter 1 (Glut-1) and Carbonic
Anhydrase 9 (CAIX).
Methods
Human breast tumor samples
Forty specimens of invasive breast carcinoma, surgically
resected between 2004 and 2006, were derived from the
archives of the Department of Pathology, University Med-
ical Center Utrecht, The Netherlands. Anonymous use of
leftover tumor material is part of the standard agreement
with patients in our hospital [22], so no explicit ethical
approval or informed consent was needed according to
Dutch law. The Science Committee of the Department of
Pathology of the University Medical Center Utrecht
approved the use of frozen section material. For all speci-
mens, formalin-fixed, paraffin embedded material as well
as fresh-frozen tissue was available. Thirty cancers were of
ductal type, 3 were lobular, 3 ducto-lobular, 3 mucinous
and 1 was a medullary carcinoma. All carcinomas were
histologically graded according the Bloom and Richard-
son (B&R) grade [23,24]. Necrosis was noted on the same
sections, and the mitotic activity index was assessed as a
marker of proliferation as previously described [25].
Estrogen (ER) and progesterone receptor (PR) status were
assessed by standard immunohistochemistry.
In situ hybridization
The probe for BNIP3 mRNA in situ hybridization was syn-
thesized by amplification of a 496 bp BNIP3 fragment
from human placental cDNA. Primers were selected
through Primer Select (version 4.00 1993–1999, DNA
Star Inc., Madison, USA) resulting in the forward primer
sequence 5'GCCCGGGATGCAGGAGGAGA and the
reverse primer sequence 5'GAGCAGCAGAGATGGAAG-
GAAAAC. Primers were purchased from Eurogentec S.A,
Seraing, Belgium. PCR conditions were as follows: one
denaturing cycle at 95°C for 5 min, followed by 30 cyclesBMC Cancer 2009, 9:175 http://www.biomedcentral.com/1471-2407/9/175
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of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min before
a final extension step at 72°C for 10 min.
These primers resulted in a primary PCR product of 496
bp, which was sequenced to assure a 100% nucleotide
match with BNIP3 mRNA. A re-PCR was performed to
label the BNIP3 PCR-product with digoxigenine, by
replacing part of the dTTP in the PCR mix by Dig-11-dUTP
(Boehringer-Mannheim GmbH, Mannheim, Germany).
Digoxigenine-labeled PCR-products were purified and
used as probe for in situ hybridization.
Fresh frozen sections of 8 μm were fixed in 4% formalde-
hyde for 1 h at room temperature. After washing, endog-
enous peroxidase was blocked with 0.3% H2O2  in
phosphate buffered saline (PBS) for 20 min. The cells
were made accessible for probes by protein K (0.1 μg/ml
in PBS) at 37°C and Triton X100 (0.005% in PBS) treat-
ment. Sections were subsequently dehydrated, air dried
and incubated with 25 μl hybridization mix (30% forma-
mide, Tris-EDTA buffer, 20× SSC, yeast tRNA, herring
sperm DNA and denatured probe) for 10 min at 47°C on
a hot plate to stretch the mRNA, followed by 18 h incuba-
tion at 37°C in a humid atmosphere.
After hybridization, slides were washed and the hybrid-
ized probe was detected by Polyclonal Rabbit Fab-2 anti-
digoxigenine/HRP (1:4000 DakoCytomation, Glostrup,
Denmark) in PBS/1% bovine serum albumin and visual-
ized by Tyramide FITC (1:50 in amplification diluent
(Perkin Elmer, Boston, USA). DNA in the nucleus was vis-
ualized with 4 μg/ml propidiumiodide (Sigma Chemicals,
St. Louis, USA) in PBS. After washing, the slides were
embedded in Fluorescent Mounting Medium (Dakocyto-
mation).
Assessment of in situ hybridization
The pVHL defective cell line RCC10 [26], derived from a
sporadic renal clear cell cancer, was used as a positive con-
trol for BNIP3 expression, and a pVHL wild type cell line
(20) and a slide without the denatured probe were used as
negative controls. The results with these control cell lines
were checked by RT-PCR with both BNIP3-specific prim-
ers and primers for Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) as household gene.
Hybridized tissues were analyzed using a confocal laser
scanning microscope (Leica TCS, Rijswijk, The Nether-
lands). Stromal macrophages and lymphocytes served as
internal control for BNIP3 expression, as they showed a
similar strong mRNA expression in all slides, as confirmed
by immunohydrido double staining for CD68 respec-
tively CD3 (data not shown), whereas tumor BNIP3 sig-
nal intensity differed between the different samples.
Samples were binary scored as negative/weak or positive.
Immunohistochemistry
Serial sections of 4 μm of paraffin embedded material of
each specimen were deparaffinized and rehydrated in
graded alcohol. Endogenous peroxidase activity was
blocked by 0.3% hydrogen peroxide in PBS for 20 min.
Antigen retrieval was performed by boiling the slides 20
min in 10 mM citrate buffer (pH 6.0) for BNIP3, CAIX and
Glut-1, and in EDTA buffer (pH 9.0) for HIF-1α immuno-
histochemistry. To avoid non-specific binding of BNIP3,
slides were pre-incubated with 10% normal swine serum
in PBS. Thereafter slides were incubated with antibodies
against BNIP3 (Rabbit polyclonal BNIP3, Biocarta Europe
GmbH, Hamburg, Germany, dilution 1:1000), CAIX
(Rabbit polyclonal, Abcam, Cambridge, UK, dilution
1:1000), HIF-1α (Mouse monoclonal, BD Transduction
Laboratories, Lexington, USA dilution 1:50) or Glut-1
(Dako, dilution 1:200).
Incubation with anti-BNIP3 and anti-HIF-1α was done
overnight at 4°C, and with anti-CAIX and anti-Glut-1 at
room temperature for 1 h.
After incubation, slides were washed and incubated with
Powervision (Immunologic, Duiven, The Netherlands),
final staining was developed by adding 3,3 diaminoben-
zidine tetrahydrochloric acid in PBS (1.5% H2O2) and
slides were counterstained with haematoxylin.
A renal clear cell carcinoma (CAIX, Glut-1, BNIP3), an
invasive breast cancer (HIF-1α,) and placental tissue
(BNIP3) were used as controls for immunohistochemistry
[27]. Negative controls were obtained by omission of the
primary antibodies.
Quantification of immunohistochemistry
All slides were scored independently by two pathologists
(EAK/PJvD). Samples were binary scored as negative/
weak or positive. When possible, both the tumor and the
benign tissue were scored. Glut-1 as well as CAIX staining
were scored as positive when membrane staining was
seen. For HIF-1α the percentage of positive nuclei was
scored as well as the topography: perinecrotic, diffuse or a
combination of both. Only homogenously and darkly
stained nuclei were considered and a percentage of ≥ 1%
positive nuclei was considered positive in line with previ-
ous studies. [28].
Statistical analysis
Fisher's exact test (GraphPad Instat, version 3.01, Graph-
pad Software Inc., San Diego, USA) was used to test the
correlation between BNIP3 in situ hybridization and
immunohistochemistry and the other immunohisto-
chemical and clinicopathological features. For HIF-1α,
the traditional threshold of 5% was used. Two-sided p-
values < 0.05 were considered significant.BMC Cancer 2009, 9:175 http://www.biomedcentral.com/1471-2407/9/175
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Results
In situ hybridization
The positive control RCC10 cell line showed an intense
signal in the cytoplasm (Fig. 1a), whereas cells of the
pVHL wild type cell line showed no or very low BNIP3-
mRNA signal (Fig. 1b). RT-PCR for BNIP3 band resulted
in a much more intense band in the pVHL defective cell
line compared to the pVHL intact cell line (Fig 2). As
expected this effect was not seen for the household gene
GAPDH.
Sixteen of the 40 breast carcinomas (40%) were positive
for BNIP3 mRNA. In all cases the signal was strong
throughout the tumor, and tumor cell staining was often
granular (Fig 3a), compared to the more diffuse signal in
macrophages. In the remaining 60% of cases, tumor cells
were negative or had only a very weak cytoplasmic signal
(Fig 3c), whereas the macrophages still had their diffuse
strong signal.
Immunohistochemistry
Twenty-three out of 40 tumors (57%) were positive for
BNIP3 protein (Fig 3b). Most of these tumors had a dif-
fusely positive cytoplasmic signal throughout the tumor.
The remaining 17 cases were negative or had a very weak
expression (Fig 3d). Expression of BNIP3 protein corre-
lated with BNIP3 mRNA expression (p = 0.022).
In 35 cases there was sufficient adjacent normal breast tis-
sue that could be examined. In 8 of these 35 cases, the nor-
mal breast tissue showed nuclear staining whereas this
was rarely seen in tumor cells (Fig. 4). When tumor cells
were strongly positive, the adjacent normal tissue showed
a clearly lower signal in 13/20 (65%) of cases, whereas the
normal tissue showed a strong signal similar to the tumor
cells in 7/20 (35%) of cases. In 6/15 (40%) of cases where
tumor cells had a very low signal or no BNIP3 expression,
the normal breast tissue showed more BNIP3 expression
than the tumor cells.
HIF-1α was positive in 24/40 tumors (60%), 8 of them in
a perinecrotic and 16 in a diffuse pattern. CAIX and Glut-
1 membrane staining were seen in 16/40 (40%) and 15/
40 (38%) of cancers, respectively. Figure 5 shows some
representative examples. There was a significant correla-
tion between expression of Glut-1 and CAIX (p = 0.018).
CAIX and Glut-1 expression was absent in normal tissue
surrounding the tumors.
In situ hybridization for BNIP3-mRNA Figure 1
In situ hybridization for BNIP3-mRNA. BNIP3-mRNA 
(green) in control cells. Nuclei are visualized with Propidiu-
miodide (red). (a) BNIP3 mRNA expression in the pVHL 
defective cell line RCC10. (b) BNIP3 mRNA expression in a 
pVHL wild type cell line.
RT-PCR results in duplicate Figure 2
RT-PCR results in duplicate. A pVHL wild type cell line 
with (a) BNIP3 amplicon compared to a pVHL defective cell 
line with (b) BNIP3 amplicon. As control lane (c) shows a 
pVHL wild type cell line with GAPDH amplicon, compared to 
a pVHL defective cell line (d) with GAPDH amplicon. Lane 
(e) shows negative H2O control, and (f) and (g) show positive 
controls with placental cDNA with BNIP3 amplicon (f) and 
with GAPDH amplicon (g).
In situ hybridization and immunohistochemistry for BNIP3  (original magnification 20×) Figure 3
In situ hybridization and immunohistochemistry for 
BNIP3 (original magnification 20×). (a) BNIP3 mRNA 
expression in a positive tumor and (b) strong BNIP3 protein 
expression in the same tumor. (c) BNIP3 mRNA negative 
tumor with presence of positive stromal macrophages as 
internal controls and (d) absence of BNIP3 protein expres-
sion in the same tumor.BMC Cancer 2009, 9:175 http://www.biomedcentral.com/1471-2407/9/175
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Positive HIF-1α staining was typically associated with
necrosis. Of the 24 HIF-1α positive tumors, 12 showed
CAIX (p = 0.006) and 12 showed Glut-1 expression (p =
0.017), especially those with necrosis. Most diffusely pos-
itive HIF-1α cases were Glut-1 negative (69%); 50% were
negative for CAIX.
Neither BNIP3 mRNA nor protein status showed signifi-
cant relations with HIF-1α status (Table 1). BNIP3 was
however, more often although not significantly expressed
in diffusely HIF-1α positive cases (10/16, 62%) than in
perinecrotic HIF-1α positive cases (2/6, 33%) (p = 0.353).
BNIP3 protein and mRNA expression failed to correlate
with CAIX or Glut-1 expression (Table 1).
Clinicopathological features
As shown in Table 2, tumors negative for BNIP3 protein,
had a significantly higher frequency of axillary lymph
node metastases than tumors with BNIP3 expression
(82% vs 39%, p = 0.010). For BNIP3 mRNA the same
inverse association was seen (p = 0.001). The mitotic
index showed a similar inverse association with BNIP3
protein expression (p = 0.027). Tumor size, histological
grading, necrosis, ER and PR were not significantly associ-
ated with BNIP3 protein expression (see Table 2), as for
BNIP3 mRNA.
Discussion
The aim of the present study was to investigate the expres-
sion of BNIP3 in invasive breast cancer at the mRNA and
protein level in correlation with the hypoxic response and
clinicopathological features. Twenty three out of 40
tumors (57%) were positive for BNIP3 protein. The
remaining 17 cases were negative or had a very weak
expression. Expression of BNIP3 protein correlated with
BNIP3 mRNA expression (p = 0.022).
To test the hypoxic response in invasive breast carcinomas
in relation to BNIP3, we also examined the expression of
HIF-1α and its target genes Glut-1 and CAIX [29-31].
CAIX and Glut-1 showed the expected positive correlation
with HIF-1α (p = 0.006, p = 0.017, respectively), espe-
cially with perinecrotic HIF-1α [31], indicating that the
study group is large enough to study the hypoxic response.
Of all tumors tested, 16 showed BNIP3 mRNA expression.
Twelve (75%) of these also had HIF-1α expression. The
remaining 25% had no HIF-1α, but did show BNIP3
mRNA. Thereby, the correlation between HIF-1α protein
and BNIP3 was not significant at the mRNA or protein
level. In a previous study [19], perinecrotic expression of
BNIP3 mRNA and protein was reported in DCIS, but it
was not mentioned whether this was also seen in invasive
cancer, which we did not find. Also in another recent
study [21] there was no association between HIF-1α and
BNIP3. There are therefore no firm clues that BNIP3
expression in invasive breast cancer is hypoxia dependent.
Induction of BNIP3 may however also occur through non-
hypoxic stimulation. The zinc-finger protein PLAGL2 is
for example able to increase BNIP3 levels, but is inde-
pendent of the hypoxia-responsive element in the BNIP3-
promoter [32]. In this current study twenty four tumors
(60%) had no BNIP3 mRNA expression. A likely explana-
Immunohistochemistry for BNIP3 in 2 cases of invasive  breast cancer (original magnification 40×) showing nuclear  staining in adjacent normal breast tissue (a and c), while  tumor cells of the same specimens show only cytoplasmic  expression (b and d) Figure 4
Immunohistochemistry for BNIP3 in 2 cases of inva-
sive breast cancer (original magnification 40×) show-
ing nuclear staining in adjacent normal breast tissue 
(a and c), while tumor cells of the same specimens 
show only cytoplasmic expression (b and d).
Representative examples of immunohistochemical staining  for (a) diffuse HIF-1α, (b) perinecrotic HIF-1α, (c) CAIX and  (d) Glut-1 in an invasive breast cancer (b, c, d same case) Figure 5
Representative examples of immunohistochemical 
staining for (a) diffuse HIF-1α, (b) perinecrotic HIF-
1α, (c) CAIX and (d) Glut-1 in an invasive breast can-
cer (b, c, d same case). Original magnification 40×.BMC Cancer 2009, 9:175 http://www.biomedcentral.com/1471-2407/9/175
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tion for the absence of BNIP3 mRNA could be methyla-
tion of the BNIP3-promoter, which would result in
silencing of the gene. This has been shown in pancreatic
adenocarcinoma where the promoter of BNIP3 turned out
to be methylated in all BNIP3-negative pancreatic cancer
cell lines and in eight out of 10 pancreatic adenocarci-
noma samples [12]. Impaired hypoxia induced BNIP3
expression has also been detected in other malignancies.
Sixty six percent of the primary colorectal and 49% of the
gastric cancers showed BNIP3 methylation [13,14]. Also
in haematological malignancies methylation of the
BNIP3 gene has been described, although less frequently
[14]. BNIP3 promoter methylation in breast cancer has
however not yet been described.
Another mechanism of mediation of BNIP3 activity may
be intranuclear sequestration of BNIP3 protein, that has
been reported in glial cells of the normal brain and in
glioblastoma multiforme [33]. In our study, we did not
find nuclear BNIP3 protein in tumors cells, but in 23% of
cases in adjacent normal breast tissue. This fits with the
concept of intranuclear sequestration of BNIP3 in normal
breast tissue, but the exact mechanism remains unclear
and should be part of further research.
Table 1: Association between BNIP3 mRNA and protein expression and the hypoxia response proteins in invasive breast cancer (n = 
40).
BNIP3 mRNA BNIP3 protein
Grouping Low High p-value Low High p-value
HIF-1α 0 12 4 0.188 5 11 0.332
≥ 1% 12 12 12 12
Glut-1 Negative/cytoplasmic staining 17 8 0.204 10 15 0.749
Membrane staining 7 8 7 8
CAIX Negative/cytoplasmic staining 16 8 0.338 9 15 0.522
Membrane staining 8 8 8 8
Table 2: Association of BNIP3 mRNA and protein expression with clinicopathological features in invasive breast cancer (n = 40).
BNIP3 mRNA BNIP3 protein
Feature* Low High p-value Low High p-value
Lymph node status
Negative 5 12 0.001 3 14 0.009
Positive 19 4 15 9
MAI (2 mm2)
1–12 9 9 0.335 4 14 0.027
≥ 13 15 7 13 9
ER
Negative 7 6 0.733 5 8 1.000
Positive 17 10 12 15
PR
Negative 12 7 0.755 10 9 0.337
Positive 12 9 7 14
Tumor size
0–2 cm 7 6 0.733 3 10 0.103
> 2 cm 17 10 14 13
Histological grade
I/II 11 10 0.349 6 15 0.108
III 13 6 12 8
Necrosis
Negative 17 9 0.500 10 16 0.520
Positive 77 77
* MAI: mitotic activity index, ER: estrogen receptor, PR: progesterone receptor.BMC Cancer 2009, 9:175 http://www.biomedcentral.com/1471-2407/9/175
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By examining the relationship between BNIP3 expression
and clinicopathological features, we found a highly signif-
icant inverse correlation between BNIP3 expression and
presence of lymph node metastases, both on the protein
level and mRNA level, this in contrast to a previous study
[21]. Of the 24 BNIP3 mRNA negative tumors, 79% had
axillary lymph node metastases, whereas this was only
25% in the BNIP3 mRNA positive group. Furthermore,
BNIP3 expression correlated with the mitotic index,
which is known to be a strong prognostic indicator in
breast cancer [25,34]. Survival analysis is not yet possible
because of the short follow-up time, but 3 patients had
distant metastases in the lung, bones or brain at the time
of completing this study. In all three cases there was no
BNIP3 mRNA. All this implies that BNIP3 expression
could be a prognostic indicator in breast cancer.
Conclusion
BNIP3 expression is lost in a significant proportion of
invasive breast cancers, and loss of BNIP3 expression cor-
related with poor prognostic features such as positive
lymph node status and high proliferation, but not with
the hypoxic response. BNIP3 inactivation may therefore
be involved in breast carcinogenesis and deserves to be
studied as a potential prognostic indicator in breast can-
cer.
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